EHA 2023 | EPIC update: observational study of first-line acalabrutinib treatment for CLL
Nicolas Martinez-Calle, MD, PhD, Nottingham University Hospitals NHS Trust, Nottingham, UK, provides insight into the rationale and results of the observational EPIC study (NCT05557695). The study focuses on the use of first-line acalabrutinib in patients with chronic lymphocytic leukemia (CLL). Dr Martinez-Calle explains that the study reported similar results to what’s been previously reported in terms of efficacy and safety, and hopes the data from this trial will shed light on the potential benefits of using acalabrutinib as a frontline therapy in younger patients with CLL as it is not currently licensed for this indication in the UK. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
